Vascular Endothelial Factor Gene Polymorphism in Preeclampsia

Beni-Suef University

Status: Completed

Conditions: Preeclampsia

Treatments: Device: Doppler ultrasound; Diagnostic Test: PCR

Study type: Observational

Funder types: Other

Identifiers

NCT03500588

BeniSuef 15

Details and patient eligibility

About

In this study, the investigators assessed one of the released protein factors during the pathophysiology of preeclampsia. They evaluated vascular endothelial growth factor gene mutation which affects the angiogenesis in case of inadequate placentation and its association with Doppler changes in the pulsatility index of the umbilical artery.

Full description

Preeclampsia is a syndrome characterized by occurrence of hypertension and proteinuria after 20 weeks of gestation. The pathophysiology of preeclampsia involves abnormalities in the development of placental vasculature early in pregnancy may result in relative placental under perfusion/hypoxia/ischemia, which then leads to release of factors into the maternal circulation that alter maternal endothelial function and cause hypertension and other manifestations of disease .Vascular endothelial growth factor (VEGF) is a signal protein produced by cells that stimulates vasculogenesis and angiogenesis. It is part of the system that restores the oxygen supply to tissues when blood circulation is inadequate. Human VEGF gene is located on chromosome 6 and consists of 8 exons with alternate splicing, forming a family of proteins. There are several common single nucleotide polymorphisms (SNPs) in the VEGF gene, which could alter gene expression and protein production, and alter the risk of developing diseases characterized by deranged angiogenesis including preeclampsia.

Enrollment: 290 patients

Sex: Female

Ages: 18 to 45 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

More than 20 weeks gestation. Preeclamptic patients

Exclusion criteria

association with chronic disease (cardiac, hepatic, renal) and if the patient was known to have chronic hypertension.

association with auto-immune disease.

Trial design

290 participants in 2 patient groups

normotensive pregnant women more than 20 weeks gestation.

Description:

One hundred and forty-five pregnant women after 20 weeks with normal blood pressure were evaluated for VEGF gene mutation.

Treatment:

Diagnostic Test: PCR

Pregnant women after 20 weeks with preeclampsia.

Description:

One hundred and forty-five pregnant women after 20 weeks with preeclampsia were evaluated for VEGF gene mutation by using PCR and Pulsitality index of umbilical artery by doppler velocimetry.

Treatment:

Device: Doppler ultrasound

Diagnostic Test: PCR